Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.
Mads Fuglsang Kjølby
Open-label multiple dosing study in asymptomatic GRN-Frontotemporal dementia patients to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VES001.
A GuideStar-Rated Charity
© Copyright 2025. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).